

Contraceptive Technology

Eighteenth Revised Edition

Robert A. Hatcher, MD, MPH

James Trussell, PhD

Felicia H. Stewart, MD

Anita L. Nelson, MD

Willard Cates Jr., MD, MPH

Felicia Guest, MPH, CHES

Deborah Kowal, MA, PA

ARDENT MEDIA, INC.
NEW YORK

00803733

Copyright © 2004 by Contraceptive Technology Communications, Inc.

All rights reserved. No part of this book may be reproduced in any manner whatever, including information storage, or retrieval, in whole or in part (except for brief quotations in critical articles or reviews), without written permission of the publisher, Ardent Media, Inc., Box 286, Cooper Station P.O., New York, NY 10276-0286 or fax (212) 861-0998.

Bulk Purchase Discounts: For discounts on orders of 25 copies or more, please fax the number above, write the address above or call (212) 861-1501. Please state if you are a non-profit organization and the number of copies you are interested in purchasing. Bulk discount orders are nonreturnable.

Note to Book Sellers: All returns require written permission and label from the publisher. CD-ROMs returnable only if packaging unopened. Write to the address above or fax the number above for permission.

ISSN 0091-9721

ISBN 0-9664902-2-3 (Paperback with CD-ROM)

ISBN 0-9664902-3-1 (Hardcover Reference with CD-ROM)

ISBN 0-9664902-5-8 (Hardcover Reference)

ISBN 0-9664902-6-6 (Paperback)

TRADEMARKS: All brand and product names are trademarks or registered trademarks of their respective companies. It has been attempted throughout this text to distinguish proprietary trademarks from generic or descriptive terms by following the capitalization style used by the manufacturer; however, the publisher cannot attest to the accuracy of this information. Use of a term in this text should not be regarded as affecting the validity of any trademark or service mark.

1 3 5 7 9 10 6 4 2


Printed in the United States of America.

The paper used in this publication meets the minimum requirements of American National Standard for Information Sciences — Permanence of Paper for Printed Library Materials, ANSI Z39.48-1984.

DISCLAIMER

The information contained herein is intended to be used by physicians and other qualified healthcare professionals. The information is not intended to be used for medical diagnosis or treatment by persons who are not qualified healthcare professionals. Such persons should not rely upon or use the information contained herein in place of a visit, call, or consultation with, or the advice of their personal physician or other qualified healthcare provider.

Physicians and other qualified healthcare professionals should recognize that this book is to be used only as a reference aid, and that this book is not intended to be a substitute for their exercise of professional judgment. Since medical science is always changing, physicians and other qualified healthcare professionals users are advised to confirm the information contained herein with an independent source. The authors and contributors are not liable for errors and omissions.



In memory of

Charlotte Ehrengard Ellertson, MPA, PhD

March 2, 1966 – March 21, 2004

Beloved friend, inspiring colleague, visionary scholar, effective activist

00803734

Contributors to Contraceptive Technology, Eighteenth Edition

Many individuals contributed to this edition of *Contraceptive Technology*. They helped ensure the completeness, accuracy, timeliness, and usefulness of the information contained herein. The Authors (listed in the first grouping) alone are responsible for errors and opinions.

Authors

Willard Cates Jr., MD, MPH
Felicia Guest, MPH, CHES
Robert A. Hatcher, MD,
MPH
Deborah Kowal, MA, PA
Anita L. Nelson, MD
Felicia H. Stewart, MD
James Trussell, PhD

Daniel Bao
Sharon Bell
James Bellinger, PAC
Kelly Blanchard, MSc
Paul Blumenthal, MD, MPH
Lynn Borgatta, MD, MPH
Michael Bracher, PhD
Glenn D. Braunstein, MD
Michael Burnhill, MD
Josefina J. Card, PhD
Eli Carter
Philip D. Darney, MD, MSc
Jacqueline Darroch, PhD
Jennifer Del Medico
Rosalie Dominik, DrPH
Laneta Dorflinger, PhD
Batra Elul, MSc
Thomas J. Espenshade,
MAT, PhD
Paul Feldblum, PhD
Monica M. Gaines, MBMA
Joan Mogul Garrity
Vanessa Garver
Vickey Gibbons
David Gittelman
John Guillebaud, MA,
FRCSE, FRCOG, MFFP
Polly F. Harrison, PhD
Stanley K. Henshaw, PhD
Douglas Huber, MD, MSc
Ken Hunt
Timothy Johnson, PhD
Kirtly Parker Jones, MD
Mary L. Kamb, MD, MPH
Leslie M. Kantor, MPH
Cynthia Kay
Maxine Keel
Philip Kestelman, MA, MSc
Douglas Kirby, PhD
Ronald L. Kleinman, MD
Lorraine Klerman, DrPH
Jacqueline Koenig, MSB
Miriam H. Labbok, MD,
MPH
Virginia Lamprecht, RN,
BSN, MSPH
Deanna Lewis, BA

Mark C. Maltzer, MD
Rebecca Maynard, PhD
Jack Moseley, MD
Kathryn Murrell, MA
LeRoy E. Nelson
Colleen O'Donnell
Chloe O'Gara, EdD
David Olive, MD
Maureen Paul
Herbert Peterson, MD
Linda Piccinino, MPS
Susan Pinsky, MD
Linda S. Potter, DrPH
Malcolm Potts, MB, BChir,
PhD
Lisa Rarick, MD
Roberto Rivera, MD
Jeffrey Sacks, MD
Gigi Santow, PhD
Karena Sapsis, MPH, CHES
Margaret Scarlett, DDS
George Schmid, MD
Sharon Schnare, FNP,
CNM, MSN
James Shelton, MD, MPH
R.V. Short, PhD, ScD
Irving Sivin, MA
Richard Soderstrom, MD
Jeff Spieler, PhD (Hon.)
Karen Stein, MD, MPH
Zena Stein, MD
Gary K. Stewart, MD, MPH
Katherine M. Stone, MD
Philip Stubblefield, MD
Kathleen Toomey, MD,
MPH
Amanda Troxler
Abby Norris Turner
Elizabeth Wentzel
Gary West, MPH
Nicole Wilcox, MPH
Beverly Winikoff, MD, MPH
Lisa Wynn, PhD
Miriam Zieman, MD

Invited Chapter Authors

Marcos Arevalo, MD, MPH
Sarah S. Brown, MSPH
Charles S. Carignan, MD
Charlotte Ellertson, MPA,
PhD*
Henry L. Gabelnick, PhD
David A. Grimes, MD
Debra W. Haffner, MDiv,
MPH
Carol J. Rowland Hogue,
PhD, MPH
Roy Jacobstein, MD, MPH
Victoria Jennings, PhD
Kathy I. Kennedy, DrPH
Luella Klein, MD
John R. Marshall, MD
Anne Brawner Namnoum,
MD
Michael S. Policar, MD,
MPH
Amy E. Pollack, MD, MPH,
FACOG
Elizabeth G. Raymond,
MD, MPH
Tara Shochet, MPH
William R. Stayton, ThD,
PhD
Marcus J. Steiner, PhD
Paul F.A. Van Look, MD, PhD
Lee Warner, PhD, MPH

Contributors

Melanie Adams
Nancy Alexander, PhD
Marcia Ann Angle, MD, MPH
Susan Ashford, MN, RNC
Christine Bachrach, PhD

Melanie Adams
Nancy Alexander, PhD
Marcia Ann Angle, MD, MPH
Susan Ashford, MN, RNC
Christine Bachrach, PhD

Table of Contents

Chapter	Page
1 Expanding Perspectives on Reproductive Health	1
<i>Deborah Kowal, MA, PA</i>	
Preventive Health Services	2
2 Sexuality and Reproductive Health	9
<i>Debra W. Haffner, MDiv, MPH</i> <i>William R. Stayton, ThD, PhD</i>	
Sexual Behavior in the United States	10
Sexual Anatomy	16
Sexual Response	17
Contraceptive Choice and Sexuality	20
Brief Introduction to Sexual Counseling	25
Introduction to Common Sexual Dysfunctions	27
3 Female Genital Tract Cancer Screening	37
<i>Michael S. Policar, MD, MPH</i>	
Screening for Cervical Cancer	38
Ovarian Cancer Screening	54
Breast Cancer Screening	56
4 The Menstrual Cycle	63
<i>Robert A. Hatcher, MD, MPH</i> <i>Anne Brawner Namnoum, MD</i>	
Menstrual Cycle Regulation	64
The Integrated Cycle	66
Fertilization and Implantation	70
5 Menopause	73
<i>Anita L. Nelson, MD</i> <i>Felicia H. Stewart, MD</i>	
Perimenopausal Issues	73
Menopause	77
Summary	100
6 Menstrual Problems and Common Gynecologic Concerns	109
<i>Anita L. Nelson, MD</i>	
Menstrual Problems	109
Gynecologic Problems	133
Sexual Dysfunction	143

* Deceased, March 21, 2004.

Chapter		Page
7	HIV/AIDS and Reproductive Health	153
	<i>Felicia Guest, MPH, CHES</i>	
	HIV Prevention in the Reproductive Health Care Setting	155
	HIV Testing and Counseling	165
	Medical Care and Psychosocial Support for Infected Women	174
	Workplace Safety	183
8	Reproductive Tract Infections	191
	<i>Willard Cates Jr., MD, MPH</i>	
	Magnitude and Risks of RTIs	192
	RTI Prevention and Personal Behaviors	193
	Assessment, Diagnosis and Treatment in the Reproductive Health Care Setting	195
	Alphabetical Catalog of Reproductive Tract Infections	201
9	The Essentials of Contraception: Efficacy, Safety, and Personal Considerations	221
	<i>James Trussell, PhD</i>	
	Efficacy: "Will It Work?"	224
	Safety: "Will It Hurt Me?"	235
	Noncontraceptive Benefits	240
	Personal Considerations	240
10	Education and Counseling	253
	<i>Felicia Guest, MPH, CHES</i>	
	Factors Influencing Education and Counseling	253
	Counseling to Support Behavior Change	260
	Informed Consent	263
11	Reproductive Health Resources	267
	<i>Tara Shochet, MPH</i>	
	<i>James Trussell, PhD</i>	
	Print and Multimedia Materials	268
	Pharmaceutical House Resources	272
	Telephone Hotlines and Websites	273
12	Emergency Contraception	279
	<i>Felicia H. Stewart, MD</i>	
	<i>James Trussell, PhD</i>	
	<i>Paul F.A. Van Look, MD, PhD, FRCOG</i>	
	Mechanism of Action	284
	Effectiveness	286
	Advantages and Indications	288
	Disadvantages and Cautions	289
	Providing Emergency Contraception	291
	Instructions for Using Emergency Contraception	298

Chapter		Page
13	Abstinence and the Range of Sexual Expression	305
	<i>Deborah Kowal, MA, PA</i>	
	The Range of Sexual Expression	307
	Indications for Abstinence or Other Forms of Sexual Expression	307
	Instructions for Using Abstinence for Contraception or STI Protection	308
14	Coitus Interruptus (Withdrawal)	311
	<i>Deborah Kowal, MA, PA</i>	
	Mechanism of Action	311
	Effectiveness	312
	Advantages and Indications	313
	Disadvantages and Cautions	313
	Instructions for Using Coitus Interruptus	314
15	Fertility Awareness-Based Methods	317
	<i>Victoria Jennings, PhD</i>	
	<i>Marcos Arevalo, MD, MPH</i>	
	<i>Deborah Kowal, MA, PA</i>	
	Mechanism of Action	317
	Effectiveness	318
	Cost	320
	Advantages and Indications	320
	Disadvantages and Cautions	321
	Providing Fertility Awareness-Based Methods	322
	Instructions for Using Fertility Awareness-Based Methods	322
16	Male Condoms	331
	<i>Lee Warner, PhD, MPH</i>	
	<i>Robert A. Hatcher, MD, MPH</i>	
	<i>Markus J. Steiner, PhD</i>	
	Mechanism of Action	332
	Effectiveness	333
	Cost	335
	Advantages and Indications	335
	Disadvantages and Cautions	338
	Providing Condoms	338
	Instructions for Using Condoms	346
17	Vaginal Spermicides	355
	<i>Willard Cates Jr., MD, MPH</i>	
	<i>Elizabeth G. Raymond, MD, MPH</i>	
	Mechanism of Action	355
	Effectiveness	356
	Cost	357
	Advantages and Indications	357
	Disadvantages and Cautions	358
	Providing Spermicides	360
	Managing Problems and Follow-Up	360
	Instructions for Using Spermicides	360

Chapter		Page
18	Vaginal Barriers: The Female Condom, Diaphragm, Contraceptive Sponge, Cervical Cap, Lea's Shield and FemCap	365
	<i>Willard Cates, Jr., MD, MPH</i> <i>Felicia H. Stewart, MD, MPH</i>	
	Mechanism of Action	366
	Effectiveness	370
	Cost	372
	Advantages and Indications	372
	Disadvantages and Cautions	373
	Providing Vaginal Barrier Methods	375
	Managing Problems and Follow-Up	382
	Instructions for Using Vaginal Barriers	383
19	Combined Hormonal Contraceptive Methods	391
	<i>Robert A. Hatcher, MD, MPH</i> <i>Anita L. Nelson, MD</i>	
	Mechanisms of Action	392
	Effectiveness	395
	Cost	397
	Oral Contraceptives	397
	Advantages and Indications	398
	Disadvantages and Health Complications	404
	Patient Selection	410
	Providing Oral Contraceptives	411
	Managing Side Effects	427
	Instructions for Using Combined Pills	438
	Transdermal Contraceptive Patch	444
	Advantages and Indications	444
	Disadvantages and Cautions	445
	Providing the Transdermal Patch	446
	Managing Problems and Follow-Up	446
	Using the Transdermal System	447
	Vaginal Contraceptive Ring	448
	Advantages	449
	Disadvantages and Cautions	449
	Providing the Vaginal Ring	450
	Managing Problems and Follow-Up	450
	Using the Vaginal Ring	450

Chapter		Page
20	Depo-Provera Injections, Implants, and Progestin-Only Pills (Minipills)	461
	<i>Robert A. Hatcher, MD, MPH</i>	
	Mechanism of Action	462
	Effectiveness	462
	Cost	465
	Advantages and Indications	466
	Disadvantages and Precautions	469
	Special Issues	478
	Depo-Provera	479
	Norplant Implants	484
	Progestin-only Pills (Minipills)	487
	Instructions for Using Minipills	487
21	Intrauterine Devices (IUDs)	495
	<i>David A. Grimes, MD</i>	
	Mechanism of Action	496
	Effectiveness	497
	Cost	497
	Advantages of Intrauterine Contraception	498
	Disadvantages of Intrauterine Contraception	499
	Special Issues	500
	Providing the IUD	502
	Managing Problems and Follow-Up	525
22	Female and Male Sterilization	531
	<i>Amy E. Pollack, MD, MPH, FACOG</i> <i>Charles S. Carignan, MD</i> <i>Roy Jacobstein, MD, MPH</i>	
	Mechanism of Action	532
	Effectiveness	532
	Cost	534
	Advantages and Indications	534
	Disadvantages and Cautions	538
	Special Issues	539
	Providing Surgical Contraception for Females	540
	Providing Vasectomy	551
	Counseling for Female Sterilization and Vasectomy	555
	Policy/Legal Issues	557
	Managing Problems and Follow-Up	558
	Reversal of Female Sterilization and Vasectomy	562
	Instructions for Female Sterilization and Vasectomy	564

Chapter		Page
23	Postpartum Contraception and Lactation	575
	<i>Kathy Irene Kennedy, DrPH</i>	
	<i>James Trussell, PhD</i>	
	Postpartum Infertility	576
	Lactational Infertility	576
	Contraceptive Benefits of Lactation	579
	Postpartum Sexuality	581
	Initiating Contraceptive Use Postpartum	582
	Postpartum Contraception for the	
	Breastfeeding Woman	585
	Breastfeeding: Advantages to the Infant	590
	Breastfeeding and HIV	591
	Breastfeeding: Effects on the Mother	592
	Instructions for and Information	
	About Breastfeeding	592
24	Contraceptive Research and Development	601
	<i>Felicia Stewart, MD</i>	
	<i>Henry L. Gabelnick, PhD</i>	
	Contraceptive Research Overview	601
	Current Contraceptive Research	607
25	Preconception Care	617
	<i>Luella Klein, MD</i>	
	<i>Felicia H. Stewart, MD</i>	
	Essential Pre-Pregnancy Information for Everyone	618
	The Preconception Care Visit	620
	Prenatal Care	627
26	Pregnancy Testing and Management of Early Pregnancy	629
	<i>Felicia Stewart, MD</i>	
	Pregnancy Evaluation	630
	Pregnancy Test Biology	631
	Pregnancy Test Options	635
	Managing Problems in Early Pregnancy	642
	Counseling Objectives With Pregnancy Diagnosis	646
27	Impaired Fertility	651
	<i>Anita L. Nelson, MD</i>	
	<i>John R. Marshall, MD</i>	
	Definitions	651
	Probability of Pregnancy	652
	Requirements for Fertility	653
	Infertility Evaluation Overview	654
	The Initial Diagnostic Evaluation	656
	Developing Diagnoses: Integrating Test Results	661
	Prognosis	664
	Description of Available Therapies	664
	Targeted Therapies for Infertility	667

Chapter		Page
28	Abortion	673
	<i>Felicia H. Stewart, MD</i>	
	<i>Charlotte Ellertson, MPA, PhD</i>	
	<i>Willard Cates Jr., MD, MPH</i>	
	Legal Status of Abortion	674
	Characteristics of Women Obtaining Abortions	675
	Deciding to Terminate a Pregnancy	676
	Selecting a Method of Abortion	677
	Pre-Abortion Procedures	679
	First-Trimester Aspiration Abortion	681
	First-Trimester Medication Abortion	682
	Second-Trimester Abortion	687
	Cautions and Precautions	689
	Preventing Abortion Complications	690
	Managing Postabortion Complications	692
	Routine Postabortion Care and Contraception	696
29	Adolescent Sexual Behavior, Pregnancy, and Childbearing	701
	<i>James Trussell, PhD</i>	
	<i>Sarah S. Brown, MSPH</i>	
	<i>Carol J. Rowland Hogue, PhD, MPH</i>	
	Levels and Trends in Abortion, Birth, and	
	Pregnancy Rates	704
	Comparison With Experience in Other Countries	705
	Determinants of Adolescent Pregnancy	711
	Sexually Transmitted Infections Among Adolescents	715
	Consequences of Adolescent Childbearing	716
	Strategies to Solve the Problem	719
	Tailoring Clinic Services for the Needs of Teens	734
30	Dynamics of Reproductive Behavior and Population Change	745
	<i>James Trussell, PhD</i>	
	Determinants of Fertility	746
	Determinants of Mortality	751
	Determinants of Migration	753
	Population Growth and Age Structure	754
	Demographic Transition	759
	Measuring Fertility, Mortality and Population Growth	762

Chapter		Page
31	Contraceptive Efficacy	773
	<i>James Trussell, PhD</i>	
	No Method	773
	Typical Use of Spermicides, Withdrawal, Periodic Abstinence, Diaphragm, Male Condom, Pill, Minipill, and Depo-Provera	774
	Perfect Use of the Cervical Cap, Sponge, and Diaphragm	775
	Typical Use of the Cervical Cap and Sponge	775
	Female Condom	776
	Perfect Use of Withdrawal and Spermicides	776
	Perfect Use of Periodic Abstinence	777
	Perfect Use of the Male Condom	778
	Perfect Use of the Pill, Minipill, Depo-Provera, and Norplant, and Typical Use of Norplant	778
	Lunelle, Evra, and NuvaRing	779
	IUD	779
	Sterilization	780
	Contraceptive Continuation	780
	Emergency Contraception	781
	The Lactational Amenorrhea Method (LAM)	781
	Index	847
	Network	867
	Forthcoming Books and Conferences	
	CD-ROM/PDA Registration Form and New Media Survey	
	Ordering Information and Order Form	

List of Tables

Table		Page
1-1	Leading causes of mortality among women	2
1-2	Periodic health screening recommendations, U.S. Preventive Services Task Force	3
2-1	Survey of sexual behaviors in the United States, 1994	11
2-2	Sexuality issues and contraceptive selection	20
2-3	Taking a sexual history	25
3-1	Pap smear screening intervals	44
3-2	Comparison of Papanicolaou reporting, CIN classification, and The Bethesda System Classification	45
3-3	2001 Bethesda System interpretation/result categories	47
3-4	Indications for colposcopy	52
3-5	Risk characteristics of breast cancer	57
5-1	Risk factors for osteoporosis and related fractures in Caucasian postmenopausal women	88
5-2	Bone mineralization medications	90
5-3	Women's Health Initiative (WHI) results	92
5-4	FDA-Approved Hormone Therapy Prescription Drugs (Not necessarily approved for these indications)	97
6-1	Range of normal values for menses	122
6-2	Etiologies of excessive uterine bleeding	122
6-3	Characteristics and types of dysfunctional uterine bleeding	125
6-4	DSM-IV criteria for premenstrual dysphoric disorder (PMDD)	128
7-1	Assessing HIV risk behaviors	156
7-2	Options for sexual intimacy and HIV prevention	158
7-3	Components of pre-test counseling	168
7-4	Post-test counseling for negative results	169
7-5	Post-test counseling for positive results	170
7-6	Possible causes of problematic HIV test results	173
7-7	Stages of HIV infection and reproductive health concerns	176
7-8	Contraception for the HIV-infected woman	181
8-1	Comparative risk of adverse consequences from coitus—RTI and unintended pregnancy	193
8-2	Effects of contraceptives on bacterial and viral RTI	194
8-3	Risks of sexually transmitted bacterial organisms and syndromes in pregnancy and childbirth	198

Table		Page
8-4	Risks of sexually transmitted viral organisms and syndromes in pregnancy and childbirth	199
9-1	Percent and number of women at risk and percent at risk currently using various methods from the 1995 National Survey of Family Growth	223
9-2	Percentage of women experiencing an unintended pregnancy during the first year of typical use and the first year of perfect use of contraception and the percentage continuing use at the end of the first year. United States.....	226
9-3	Voluntary risks in perspective	236
9-4	Major methods of contraception and some related safety concerns, side effects, and noncontraceptive benefits	241
9-5	The stages of reproductive life	242
9-6	Contraceptive method comfort and confidence scale	244
9-7	Unit costs for contraceptive methods and associated services.....	245
10-1	Counseling guide on "How to Pick a Partner"	255
10-2	Collected wisdom on education and counseling	262
11-1	Reproductive health organizations	267
11-2	Research and advocacy organizations	268
11-3	Pharmaceutical company websites and toll-free phone numbers.....	272
11-4	Hotlines and websites	273
11-5	Online resource lists	277
12-1	Twenty OCs that can be used for emergency contraception in the United States.....	280
12-2	Reasons for requesting emergency contraception, selected studies	292
12-3	Anti-nausea treatment options.....	295
12-4	Initiating ongoing contraception after ECP use	296
13-1	Percentage of women age 15-44 who report having had no sexual intercourse in the 3 months prior to NSFG interview, 1995	306
14-1	First-year probability of pregnancy for withdrawal, chance, condoms, and pills	312
15-1	First-year probability of pregnancy for women using no method, a FAB method, and barrier methods	319
16-1	Characteristics of latex, natural membrane, and synthetic condoms.....	333
16-2	First year probability of pregnancy for couples using condoms, withdrawal, diaphragm, and pill.....	334
16-3	Dialogues for negotiating condom use with sex partners.....	340
16-4	Characteristics men seek when selecting a condom, 1991 National Survey of Men.....	342
16-5	Examples of lubricant products that should and should not be used with natural rubber latex condoms	344

Table		Page
18-1	First-year probability of pregnancy for women using vaginal barrier methods.....	371
18-2	Vaginal barrier methods—guidelines for use	376
19-1	First-year probability of pregnancy for women using combined hormonal contraceptives compared with other hormonal contraceptives	396
19-2	Circulatory diseases attributable to pills	406
19-3	Medical conditions precluding OC use, as listed in pill package inserts (PPI)	412
19-4	WHO Medical eligibility criteria for low-dose combined oral contraceptives (COCs), patches and rings, 2004.....	413
19-5	Estrogenic, progestogenic, and combined effects of oral contraceptive pills	428
20-1	Delivery systems for progestin-only contraceptives and combined pills.....	463
20-2	First-year probability of pregnancy for women using hormonal contraceptives	465
20-3	Bleeding patterns over a 5-year period among women using Depo-Provera injections and Norplant implants	469
20-4	WHO medical eligibility criteria for progestogen-only contraceptives	472
20-5	Risks of 5 types of cancers in DMPA users.....	479
21-1	WHO medical eligibility criteria	507
22-1	First-year probability of pregnancy for sterilization, condoms, pills, IUDs, and implants.....	533
22-2	Cost of sterilization.....	534
22-3	Various occlusion methods and techniques (advantages and disadvantages)	536
22-4	Substitutes for meperidine anesthesia for female sterilization	550
24-1	Method timeline: date of introduction and/or FDA approval	604
24-2	The drug development process.....	605
24-3	Microbicide Clinical Trials Planned, Ongoing, or Completed.....	608
25-1	Pre-pregnancy health precautions	619
25-2	The preconception care visit	620
25-3	Mother's age and risk for chromosome abnormalities	621
25-4	Common medications that may adversely affect fetal development	626
26-1	Possible reasons for discrepancy between uterine size and menstrual dates	631
26-2	Commonly used clinic and office pregnancy tests	636
26-3	Early pregnancy danger signs.....	644
27-1	Incidence of conception over time among non-sterile couples with mean fecundability of 0.2 (pregnancy rate = 20% per month)	653
27-2	Causes of infertility in men	655
27-3	Causes of infertility in women.....	655

<i>Table</i>	<i>Page</i>
27-4 Fertile, indeterminate, and subfertile ranges for sperm measurements	657
27-5 Initial laboratory studies for evaluating fertility	658
27-6 Tests for further evaluation of the woman	659
28-1 Characteristics of women who obtained legal abortions—United States, selected years, 1972 to 1999	677
28-2 Advantages and disadvantages of early abortion methods	678
28-3 Comparison of Mifepristone Regimens	684
28-4 Warning signs after abortion	686
29-1 Pregnancies, births, and abortions to adolescents (numbers in thousands): United States, 1997	702
29-2 Percent of never-married males and females who had had sexual intercourse: United States, 1995	713
29-3 Minor's right to consent to health care	735
29-4 Quick checklist for assessing whether contraceptive services to teens are optimal (FIND, SERVE, CARE Model)	737
31-1 Percentage of women experiencing an unintended pregnancy during the first year of typical use and the first year of perfect use of contraception and the percentage continuing use at the end of the first year. United States	792
31-2 Summary of studies of pregnancy rates among women neither contracepting nor breastfeeding	794
31-3 Summary of studies of contraceptive failure: spermicides	795
31-4 Summary of studies of contraceptive failure: withdrawal	802
31-5 Summary of studies of contraceptive failure: periodic abstinence	804
31-6 Summary of studies of contraceptive failure: cervical cap and other female barrier methods with spermicide	809
31-7 Summary of studies of contraceptive failure: sponge	812
31-8 Summary of studies of contraceptive failure: diaphragm with spermicide	813
31-9 Summary of studies of contraceptive failure: male condom	818
31-10 Summary of studies of contraceptive failure: minipill	821
31-11 Summary of studies of contraceptive failure: combined oral contraceptives, vaginal rings, and patches	824
31-12 Summary of studies of contraceptive failure: injectables	833
31-13 Summary of studies of contraceptive failure: IUD	836
31-14 Summary of studies of contraceptive failure: Implants	838
31-15 Summary of studies of contraceptive failure: female sterilization ..	839
31-16 Summary of studies of contraceptive failure: vasectomy	844

List of Figures

<i>Figure</i>	<i>Page</i>
2-1 Sexual response curve	18
4-1 Regulation of the menstrual cycle	68
4-2 Menstrual cycle events: hormone levels, ovarian, and endometrial patterns and cyclic temperature and cervical mucus changes	69
5-1 Stages/nomenclature of normal reproductive aging in women	74
6-1 Diagnostic evaluation for primary amenorrhea	114
6-2 Systematic diagnostic evaluation for secondary amenorrhea	117
6-3 Flexibility in SSRI use for premenstrual syndrome (PMS)	131
9-1 Time spent in the stages of reproductive life	243
9-2 One year costs associated with contraceptive method use in the private sector	246
9-3 Five year costs associated with contraceptive method use in the private sector	247
12-1 Impact of delay in treatment on ECP effectiveness	287
12-2 Pregnancy probability by cycle day	293
15-1 CycleBeads for Standard Days method	323
15-2 Cervical secretion variations during a model menstrual cycle	325
15-3 Symptothermal variations during a model menstrual cycle	327
18-1 Reality Female Condom	367
18-2 Types of diaphragms	368
18-3 Cervical cap	368
18-4 Contraceptive sponge	369
18-5 Some women prefer to use a plastic introducer for diaphragm insertion	370
19-1 Relative potency of estrogens and progestins in selected oral contraceptives reflecting the debate about the strength of the progestins	394
19-2 Choosing a pill	423
19-3 New onset or worsening headaches in OC users	431
19-4 Vaginal Contraceptive ring: insertion	451
<i>Insert</i> Color Photos of Combined and Progestin-Only Oral Contraceptives	A-H
20-1 Norplant removal techniques	486
20-2 Sperm penetration test following progestin-only pill	488

Figure		Page
21-1-7	Copper T 380A Insertion.....	520
21-8-18	Levonorgestrel-Releasing Intrauterine System (LNG-IUS) Insertion.....	523
22-1	Tubal sterilization techniques.....	540
22-2	Minilaparotomy incision site and size.....	542
22-3	A metal elevator raises the uterus and moves it from side to side so that the uterus and tubes will be closer to the incision.....	543
22-4	Laparoscopy.....	545
22-5	A laparoscopy instrument grasps one tube in preparation for cautery or application of a ring or clip.....	545
22-6	Hysteroscopic placement of permanent birth control micro-insert within tubal lumen.....	547
22-7	Sites of vasectomy incisions.....	552
22-8	No-scalpel vasectomy.....	554
23-1	Evidence-based guidelines for breastfeeding management during the first 14 days.....	577
23-2	Schema for breastfeeding definition.....	580
23-3	LAM: lactational amenorrhea method.....	581
26-1	hCG levels during normal pregnancy.....	632
26-2	hCG levels in early pregnancy.....	633
26-3	hCG disappearance after pregnancy.....	634
28-1	Options for terminating pregnancy, by length of pregnancy.....	678
28-2	Percentage of women eligible for early medical abortion who were prescribed mifepristone, four European countries, 1990-2000.....	679
29-1	Abortions, births and pregnancies per 1,000 women aged 14-19, by age, United States, 1997.....	706
29-2	Abortions, births and pregnancies per 1,000 women aged 15-19, United States, 1970-1999.....	707
29-3	Number of births per 1,000 women aged 15-19, 1990s.....	708
29-4	Percent of never-married females and males who have had sexual intercourse before reaching selected ages, by race, United States, 1995.....	712
30-1	Age pyramids for the United States and Mexico.....	755
30-2	Age pyramids for six stable populations.....	756
30-3	The demographic transition.....	759
30-4	Doubling time and world population growth curve.....	764
30-5	Age-specific mortality rates for a typical population with expectation of life of 50 years.....	766

Expanding Perspectives on Reproductive Health

Deborah Kowal, MA, PA

- Evolving market forces and consumer expectations are changing the scope of reproductive health services.
- Many primary care providers are delivering reproductive health services. Conversely, many reproductive health care providers are delivering primary care services.
- Family planning helps not only individuals and families, but also the community at large.

In recent years, reproductive health care in the United States, in parallel with other medical disciplines, has changed to meet the challenges of evolving market forces and broadened consumer expectations. As a result, integrated reproductive health care has expanded in concept. In many cases, shifting management and insurance schemes have placed reproductive health within the domain of primary care. For an increasing number of women, the clinician who provided only family planning now often serves as their health care provider for all primary care. For others, their primary care provider now delivers the family planning services they may previously have received elsewhere.

A broader scope of family planning services includes not only fertility but also infertility, not only sexually transmitted infections (STIs) but also reproductive tract infections (RTIs) overall, not only menstruation and fertilization but also the preconceptional and interconceptional periods and menopause, and finally, not only reproductive tract problems but the wide range of risk factors that influence a woman's health in general. As reproductive health care expands in scope, however, two goals are paramount. First, the planning, or preventive focus, of family planning must remain a central activity. Second, reproductive health must be recognized for its broader public health impact.

results have not yet been substantiated by any other studies. Consensus is that it is not prudent to prescribe higher dose pills based on these preliminary data because of the increased risk of thrombosis with high doses of estrogen.¹¹ Heavier women who used extended cycles of OCs had no increase in pregnancy risk.¹²

Transdermal Patch and Contraceptive Ring

The patch and the vaginal ring have not been in use long enough to permit precise measurements of typical-use failure rates. In comparative trials, the failure rates for patches, vaginal rings, and OCs were low,^{13,14} and roughly equivalent. Successful utilization rates were statistically higher with the longer acting agents than with the pills that were taken daily. Overall, women who used the patch or vaginal ring were more likely to use their methods correctly and consistently for 13 cycles than were OC users.^{15,16} These observations suggest that, in routine practice, the newer long-acting delivery systems may be associated with lower typical-use pregnancy rates than are the pills. However, since this tantalizing possibility has not yet been demonstrated, the authors have decided to quote the same typical failure rates for the pill, the patch, and the vaginal ring (see Chapter 9, The Essentials of Contraception).

One group of potential patch users deserves special counseling. Heavier women, weighing >198 lbs, comprised 3% of the study population but experienced 30% of all the pregnancies in the clinical trial.¹⁷ This decrease in efficacy does not preclude use of the patch by heavier women but does suggest that these women may benefit from additional counseling,¹⁸ including recommending back-up contraception.

Table 19-1 First-year probability of pregnancy* for women using combined hormonal contraceptives compared with other hormonal contraceptives

Method	% of Women Experiencing an Unintended Pregnancy Within the First Year of Use		% of Women Continuing Use at One Year
	Typical Use	Perfect Use	
Combined pill and minipill	8	0.3	68
Evra Patch and Nuva Ring	8**	0.3	68
Depo-Provera	3	0.3	56
IUD			
Paragard (Copper T)	0.8	0.6	78
Mirena (LNG-IUS)	0.1	0.1	81

* See Table 9-2 for pregnancy year failure rates of all methods.

** No data available; assumed to be same as combined oral contraceptives.

Emergency Contraceptive Pills: Treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%. (See Chapter 12 for more information.)

COST

Health department family planning programs in Washington State have paid much less for OCs than for other hormonal contraceptives. In 2001, they reported paying \$1.35 per cycle of combined pills, just over one third of the cost of Depo-Provera. In Washington, the discounted cost of OCs to health departments is about 1/20th of the price charged to a private pharmacy chain.¹⁹ The cost of the pills to women paying full price at pharmacies varies somewhat but is becoming higher all the time, ranging from \$15 to \$50 or even higher per cycle. Generic brands are typically less expensive. Usually, pills cost from \$30 to \$35 per cycle, one ring costs \$40, and a pack of 3 patches (one cycle) costs \$42. This means women paying full price pay \$390 to \$455 per year out of pocket for OCs, just over \$500 for the ring and about \$550 for the patch. Women whose contraceptives are covered by insurance have to pay a co-pay each month. Purchase of OCs from the Internet, when 3 cycles are bought at a time, can reduce the price to under \$20 per cycle with delivery charges extra. Some women travel to Mexico to purchase pills over-the-counter for as little as \$3 to \$5 per cycle.

ORAL CONTRACEPTIVES

OCs are safe and effective for the vast majority of reproductive-aged women. They are the most extensively studied medications in the history of medicine. Over 80% of U.S. women born after 1945 have used the pill at some time.¹ In the United States, OCs are available only by prescription; in some other countries, they are available over the counter. The keys to successful and safe OC use are selection of appropriate OC candidates, patient motivation, and effective counseling.

Oral Contraceptive Formulations

OCs are available in either monophasic or multiphasic packaging:

- **Monophasic formulations.** Each active pill contains the same doses of the estrogen and progestin.
- **Multiphasic formulations.** The amounts of hormones in the active pills can vary throughout the cycle.
 - Biphasic pills have 2 different combinations of estrogen and progestin in the pills.
 - Triphasic formulations have 3 different combinations. Sometimes the progestin content increases in stepwise progression during the cycle, but some other formulations may also alter the amounts of estrogen given during the cycle. One formulation (Estrostep) holds the progestin dose constant and increases the estrogen content in tablets late in the cycle.

Most pill packs contain 21 active (hormone containing) pills with or without 7 placebo pills (21-pill packs versus 28-pill packs). However, one

00803743

brand (Mircette) includes 21 active pills, 2 placebo pills and 5 pills with 10 mcg EE each. Another preparation (Seasonale) has 84 active pills followed by 7 placebo pills, which reduces the number of withdrawal bleeds to 4 episodes a year. Under development are preparations containing 24 active pills and 4 placebo pills per pack.

ADVANTAGES AND INDICATIONS

Many women harbor profound misinformation about the safety and utility of OCs. A 2000 survey revealed that 41% of those interviewed believed the pill was associated with significant health hazards.²⁰ However, OCs have numerous attractive features:

General Advantages

1. **Effectiveness.** When taken correctly and consistently, OCs are very effective contraceptives that give women control over their own fertility.
2. **Safety.** Through prudent selection of users (see below), OCs are safer for a woman's health than are pregnancy and delivery. Recent large-scale studies show that OC use does not increase the risk of death among non-smokers.²¹
3. **An option throughout the reproductive years.** Healthy women can safely use OCs throughout their reproductive lives. Age itself is not a reason to avoid OCs. The noncontraceptive benefits of the pill meet the varying needs of women of all ages. Young women may benefit from reduction in severe dysmenorrhea and acne, while at the other end reproductive life, perimenopausal women may benefit from cycle control and hot flash reduction provided by OCs.
4. **Rapid reversibility.** On average, women who stop taking OCs have only a 2-week delay in return of ovulation. Some women (<3%) have a slower return to fertility—the so-called “post-pill amenorrhea”—that is diagnosed 6 months after stopping the pills. Women need to understand that OC use neither hastens nor delays the onset of menopause.

Contraceptive health benefits

1. **Reduction of maternal deaths.** The CDC calculated that there were 11.8 pregnancy-related deaths per 100,000 live births in the last decade of the 20th century, but that there was significant under-reporting.²² Embolism, hemorrhage, and pregnancy-induced hypertension were the 3 leading causes of death. Considering that nearly half the pregnancies in this country are unintended, prevention of those pregnancies could significantly decrease maternal deaths.

2. **Reduction of ectopic pregnancies.** OCs reduce the risk of ectopic pregnancy by over 90%.^{23–25} At least one in 80 pregnancies in the United States is an ectopic pregnancy, the leading cause of maternal death in the first trimester. The CDC reports that 25 women died of ectopic pregnancy in 1992.

Menstrually-related health benefits

1. **Decreased dysmenorrhea.** OCs significantly decrease menstrual cramps and pain. Although the original studies used high-dose formulations, even low-dose formulations help when given in the conventional cyclic fashion.²⁶ OC use reduces the incidence of all degrees of dysmenorrhea by 60%.²⁷ Severe dysmenorrhea was reduced by almost 90%.²⁸ In a randomized clinical trial, low-dose OC users reported fewer absences from school and work and used less pain relief medicine than placebo users. More significant relief of symptoms can be achieved by continuous or extended use, which eliminates withdrawal periods for prolonged periods of time.
2. **Decreased menstrual blood loss.** OCs decrease the number of days of bleeding and the amount of blood women lose each cycle. In women with menorrhagia, high-dose OC use reduced blood loss by 53%.²⁹ In more recent studies with low dose OCs (30 mcg EE), menstrual blood loss and duration of flow were also decreased.³⁰ Overall, a 38% to 49% reduction in menstrual blood loss was seen in another study with a 30 mcg EE preparation.^{31,32} In addition, nearly 50% of women experience a reduction in duration of menstrual bleeding with OC use.³³ Decreased menstrual blood loss reduces a woman's risk for iron deficiency anemia. If women use any of the extended cycle options, the number of withdrawal bleeds decreases, enhancing these benefits even more.
3. **Reduction in menstrually-related PMS symptoms.** OCs can reduce menstrually-related PMS symptoms such as mastalgia, bloating, cramping, and pain. Drospirenone-containing pills have also been shown to improve symptoms of water retention, negative affect, and increased appetite associated with menses.^{34,35}
4. **Decreased anovulatory bleeding.** Low-dose OC use was associated with a more than 80% improvement in dysfunctional uterine bleeding in a randomized, double blind, placebo-controlled study.³⁶
5. **Mittelschmerz relief.** By preventing ovulation, OCs can eliminate the midcycle pain some women experience with ovarian follicle swelling and oocyte extrusion.

00803744

6. **Fewer ovarian cyst problems.** Because OCs suppress ovulation, they reduce the risk of hemorrhagic corpora luteal cysts, a condition which can require surgery. Because OCs decrease stimulation of the ovaries by FSH and LH, the incidence of other functional ovarian cysts among women using high-dose OCs was also reduced. Low-dose and multiphasic formulations may help reduce postovulatory cysts;^{37,38} however, they do not protect against follicular cyst formation.^{39,40}
7. **Improvement in menstrual migraines.** Menstrual migraines are caused by estrogen withdrawal. Cyclic OC use may worsen the intensity of a woman's migraine during her menses; on the other hand, menstrual migraine symptoms may be prevented if she takes active pills every day continuously. (See the section on Headaches, in Managing Side Effects.)

General health benefits

1. **Endometrial and ovarian cancer risk reductions.** When compared with women who have never used OCs, OC users are 40% less likely to develop epithelial ovarian cancer.⁴¹ Ten years or more of use of all monophasic formulations reduces a woman's risk of developing such cancers by 80%.⁴² This protection lasts for up to two decades beyond the time the woman takes her last OC.^{42,43} Studies that focus on the newer lower dose formulations (<35 mcg EE) have found similar protection levels⁴³ even in women genetically at higher risk for developing ovarian cancer (BRCA1 mutation cancers).^{43,44} Formulations with high doses of progestins protected more than twice as well as OCs with a lower dose of progestins.⁴⁵ Women with a family history of ovarian cancer enjoy a greater benefit of ovarian cancer risk reduction than women with no family history.⁴⁶ Women with first-degree relatives with ovarian cancer who use OCs for 4 years had a 90% reduction in ovarian cancer risk.⁴⁷ One study found that increased duration of OC use did not reduce further the risk of ovarian cancer in BRCA1 or BRCA2 mutation carriers and cautioned against routine use of OCs for chemoprevention.⁴⁸ On the other hand, current information has led some to suggest that OCs should be offered to women at high risk for ovarian cancer even if contraceptive benefit is not required.⁴⁹

OC use for at least 12 months reduces a woman's risk of developing endometrial cancer by about 40%.⁵⁰ That risk reduction is increased to 80% in women who use OCs for at least a decade.⁴¹ This protection also endures for up to 20 years after OC discontinuation.⁵¹

2. **Decreased risk of benign breast conditions.** OC users are less likely to develop fibrocystic breast changes, cysts, or fibroadenoma and are less likely to experience progression of those breast

COLOR PHOTOS

of Combined and Progestin-Only Oral Contraceptives

The eight color pages of pills are organized as follows:

Color photos of pills from lowest to highest estrogen dose

- Progestin-only pills with **no estrogen**: Micronor, NOR-QD, and Ovrette
- Lowest estrogen pills with **20 micrograms** of the estrogen, ethinyl estradiol: Alesse, Levlite, LoEstrin 1/20, and Mircette
- All of the **30- and 35-microgram** pills (all ethinyl estradiol)
- All of the **phasic** pills
- Highest estrogen pills, with **50 micrograms** of estrogen (ethinyl estradiol OR mestranol). Mestranol is converted in the body to ethinyl estradiol; 50 mcg of mestranol is equivalent to 35 mcg of ethinyl estradiol

** There are prominent horizontal or vertical parallel lines ("equal signs") between pills which are pharmacologically exactly the same. The color and packaging of pills dispensed in clinics may differ from pills in pharmacies.*

Pills you can prescribe as emergency contraceptive pills

00803745

PROGESTIN - ONLY PILLS

MICRONOR® TABLETS
28-DAY REGIMEN
 (0.35 mg norethindrone) (lime green)
 Ortho-McNeil

=



NOR-QD® TABLETS
 (0.35 mg norethindrone) (yellow)
 Watson



OVRETTE® TABLETS
 (0.075 mg norgestrel) (yellow)
 Wyeth

COMBINED PILLS - 20 microgram PILLS

ALESSE - 28 TABLETS
 (0.1 mg levonorgestrel/20 mcg ethinyl estradiol)
 (active pills pink)
 Wyeth

=



LEVLITE™ - 28 TABLETS
 (0.1 mg levonorgestrel/20 mcg ethinyl estradiol)
 (active pills pink)
 Berlex

=

AVIANE
 (0.1 mg
 levonorgestrel/
 20 mcg ethinyl
 estradiol)
 (active pills
 orange)
 Barr
 Laboratories



LOESTRIN® FE 1/20
 (1 mg norethindrone acetate/20 mcg ethinyl
 estradiol/75 mg ferrous fumarate [7d])
 (active pills white)
 Pfizer



MIRCETTE - 28 TABLETS
 (0.15 mg desogestrel/ 20 mcg ethinyl estradiol X 21 (white)/
 placebo X 2 (green)/10 mcg ethinyl estradiol X 5 (yellow)
 Organon

COMBINED PILLS - 30 microgram PILLS

LEVLEN® 28 TABLETS
 (0.15 mg levonorgestrel/30 mcg ethinyl estradiol)
 (active pills light orange)
 Berlex

=



LO/OVRAL®-28 TABLETS
 (0.3 mg norgestrel/30 mcg ethinyl estradiol)
 (active pills white)
 Wyeth

||



NORDETTE®-28 TABLETS
 (0.15 mg levonorgestrel/30 mcg ethinyl estradiol)
 (active pills light orange)
 Monarch



LOW-OGESTREL - 28
 (0.3 mg norgestrel/30 mcg ethinyl estradiol)
 (active pills white)
 Watson

||



SEASONALE
 (0.15 mg levonorgestrel/30 mcg ethinyl estradiol)
 84 active pills followed by 7 placebo pills
 Barr Laboratories

=



LEVORA TABLETS
 (0.15 mg levonorgestrel/30 mcg ethinyl estradiol)
 (active pills white)
 Watson



DESOGEN® 28 TABLETS
 (0.15 mg desogestrel/30 mcg ethinyl estradiol)
 (active pills white)
 Organon



LOESTRIN® 21 1.5/30
 (1.5 mg norethindrone acetate/ 30 mcg ethinyl estradiol)
 (active pills green)
 Pfizer

||



ORTHO-CEPT® TABLETS
28-DAY REGIMEN
 (0.15 mg desogestrel/30 mcg ethinyl estradiol)
 (active pills orange)



YASMIN 28 TABLETS
 (3.0 mg drospirenone/30 mcg ethinyl estradiol)
 (active pills yellow)
 Berlex

00803746

COMBINED PILLS - 35 microgram PILLS

OVCON® 35 28-DAY
(0.4 mg norethindrone/35 mcg ethinyl estradiol)
(active pills peach)
Warner-Chilcott
Now there is a chewable Ovcon-35 pill! ←



BREVICON® 28-DAY TABLETS
(0.5 mg norethindrone/35 mcg ethinyl estradiol)
(active pills blue)
Watson




DEMULEN® 1/35-28
(1 mg ethynodiol diacetate/35 mcg ethinyl estradiol)
(active pills white)
Pharmacia



ORTHO-CYCLEN® 28 TABLETS
(0.25 mg norgestimate/35 mcg ethinyl estradiol)
(active pills blue)
Ortho-McNeil



MODICON® TABLETS 28-DAY REGIMEN
(0.5 mg norethindrone/35 mcg ethinyl estradiol)
(active pills white)
Ortho-McNeil



ZOVIA® 1/35E-28
(1 mg ethynodiol diacetate/35 mcg ethinyl estradiol)
(active pills light pink)
Watson

COMBINED PILLS - 35 microgram PILLS (continued)

NORETHIN 1/35E-28
(1 mg norethindrone/35 mcg ethinyl estradiol)
(active pills white)
Shire
||



ORTHO-NOVUM® 1/35 28 TABLETS
(1 mg norethindrone/35 mcg ethinyl estradiol)
(active pills peach)
Ortho-McNeil
||



NORINYL® 1+35 28-DAY TABLETS
(1 mg norethindrone/35 mcg ethinyl estradiol)
(active pills yellow-green)
Watson



NECON 1/35-28
(1 mg norethindrone/35 mcg ethinyl estradiol)
(active pills dark yellow)
Watson

COMBINED PILLS - PHASIC PILLS

ORTHO TRI-CYCLEN® LO - 28 TABLETS
(norgestimate/ethinyl estradiol)
0.18 mg/25 mcg (7d) (white),
0.215 mg/25 mcg (7d) (light blue),
0.25 mg/25 mcg (7d) (dark blue)
remaining 7 placebo pills are green
Ortho-McNeil



CYCLESSA
(desogestrel/ethinyl estradiol-triphasic regimen)
0.1 mg/25 mcg (7d) (light yellow)
0.125 mg/25 mcg (7d) (orange)
0.150 mg/25 mcg (7d) (red)
Organon



TRIVORA®
(levonorgestrel/ethinyl estradiol-triphasic regimen)
0.050 mg/30 mcg (6d), 0.075 mg/40 mcg (5d),
0.125 mg/30 mcg (10d) (pink)
Watson



TRIPHASIL® 28 TABLETS
(levonorgestrel/ethinyl estradiol-triphasic regimen)
0.050 mg/30 mcg (6d) (brown),
0.075 mg/40 mcg (5d) (white),
0.125 mg/30 mcg (10d) (light yellow)
Wyeth



TRI-LEVLEN® 28 TABLETS
(levonorgestrel/ethinyl estradiol-triphasic regimen)
0.050 mg/30 mcg (6d) (brown),
0.075 mg/40 mcg (5d) (white),
0.125 mg/30 mcg (10d) (light yellow)
Berlex

00803747

COMBINED PILLS - PHASIC PILLS (continued)

**ORTHO-NOVUM® 10/11
28 TABLETS**
(norethindrone/ethinyl estradiol)
0.5 mg/35 mcg (10d) (white),
1 mg/35 mcg (11d) (peach)
Ortho-McNeil



JENEST 28 TABLETS
(norethindrone/ethinyl estradiol)
0.5 mg/35 mcg (7d) (white),
1 mg/35 mcg (14d) (peach)
Organon



**TRI-NORINYL®
28-DAY TABLETS**
(norethindrone/ethinyl estradiol)
0.5 mg/35 mcg (7d) (blue),
1 mg/35 mcg (9d) (yellow-green),
0.5 mg/35 mcg (5d) (blue)
Watson



**ORTHO-NOVUM® 7/7/7
28 TABLETS**
(norethindrone/ethinyl estradiol)
0.5 mg/35 mcg (7d) (white),
0.75 mg/35 mcg (7d) (light peach),
1 mg/35 mcg (7d) (peach)
Ortho-McNeil



**ORTHO TRI-CYCLEN®
28 TABLETS**
(norgestimate/ethinyl estradiol)
0.18 mg/35 mcg (7d) (white),
0.215 mg/35 mcg (7d) (light blue),
0.25 mg/35 mcg (7d) (blue)
Ortho-McNeil



**ESTROSTEP® FE
28 TABLETS**
(norethindrone acetate/ethinyl estradiol)
1 mg/20 mcg (5d) (white triangular),
1 mg/30 mcg (7d) (white square),
1 mg/35 mcg (9d), 75 mg ferrous
fumarate (7d) (white round)
Pfizer

COMBINED PILLS - 50 microgram PILLS

Pills with 50 micrograms of mestranol are not as strong as pills with 50 micrograms of ethinyl estradiol



**ORTHO-NOVUM® 1/50
28 TABLETS**
(1 mg norethindrone/50 mcg mestranol)
(active pills yellow)
Ortho-McNeil



OVRAL - 21 TABLETS
(0.5 mg norgestrel/50 mcg ethinyl estradiol)
(active pills white)
Wyeth

=

OGESTREL
Watson



DEMULEN® 1/50-28
(1 mg ethynodiol diacetate/50 mcg ethinyl estradiol)
(active pills white)
Pharmacia
A Division of Pfizer



OVCON® 50 28-DAY
(1 mg norethindrone/50 mcg ethinyl estradiol)
(active pills yellow)
Warner-Chilcott

00803748

PILLS AS EMERGENCY CONTRACEPTIVES:

2 Different Approaches: Progestin-Only Pills OR Combined Pills

PROGESTIN-ONLY PILLS

Plan B

1 + 1 pill 12 hours apart OR
2 Plan B pills ASAP
after unprotected sex

20 + 20 pills 12 hours apart

Ovrette (yellow pills)

(Plan B and Ovrette are NOT carried
in all pharmacies. Check in advance.
Ask your pharmacy to carry Plan B



plan B[®]
(LEVONORGESTREL)

PLAN B


Antinausea meds not necessary ←

COMBINED ORAL CONTRACEPTIVES

2 + 2 pills 12 hours apart

Preven[®] (blue pills) OR
Ogestrel (white pills)
Ovral (white pills)

(Preven Ogestrel and Ovral are NOT carried
in all pharmacies. Check in advance.)*



PREVEN[®]

4 + 4 pills 12 hours apart

Low-Ogestrel (white pills)
Lo-Ovral (white pills),
Levora (white pills) OR
Levlen (light orange pills) OR
Nordette (light orange pills) OR
Triphasil (yellow pills),
Tri-Levlen (yellow pills) OR
Trivora (pink pills)

5 + 5 pills 12 hours apart

Alesse (pink pills) OR
Levlite (pink pills) OR
Aviane (orange pills)

Have your patient take
antinausea medication an
hour before the first dose if
using any of the combined
oral contraceptives as
emergency contraception.
This is not necessary if
using Plan B.

* NOTE: Preven Discontinued in 2004

conditions.⁵² In one case-controlled study with over 500 women, the risk of benign breast conditions was lower in the OC users, and significantly less in women who started OC use before their first full-term pregnancy.⁵³ Women who have hyperplasia with atypia are a notable exception; OC use does not confer any protection to these women.⁵⁴

3. **Improvement of androgen sensitivity or androgen-excess conditions** (e.g., polycystic ovary syndrome). In prospective, randomized, placebo-controlled, double-blind trials, women who use OCs have been shown to have a reduction in the numbers and size of acne lesions.^{55,56} Dutch surveys reported that OC use reduced the prevalence of acne by over two-thirds.⁵⁷ Only 2 formulations have received FDA approval for treatment of mild to moderate acne (OrthoTri-Cyclen and Estrostep), but other formulations with little or no androgenicity and relatively high estrogenicity increase sex hormone binding globulin (SHBG), which is understood to be the main mechanism for OC use in acne treatment. Women with excessive facial or body hair (hirsutism) have reduction in the hair shaft diameter with OC use.^{58,59}
4. **Reduced risk of hospitalization for gonorrheal PID.** The risk of cervical gonorrhea infection spreading into the uterus (endometritis), fallopian tubes (salpingitis) or other pelvic organs (PID) is reduced. In studies conducted in the 1980s, when fewer women with PID were treated on an outpatient basis, the risk of hospitalization for PID was reduced by 50% to 60% in current users after 12 months of use.⁶¹ The exact mechanism of this protection is not known. It may be due to thickened cervical mucus blocking sperm penetration, atrophy of the endometrium (fewer days of bleeding), and/or reduction of movement of pathogens into the tube. Similar reductions are not seen in the risk of chlamydial PID.⁶⁰
5. **Suppression of endometriosis.** Current or recent OC use is associated with a lower incidence of symptomatic endometriosis, especially among parous women (see Chapter 6, Menstrual Problems and Common Gynecologic Concerns).⁶² The risk of endometrioma was found to be significantly reduced in current OC users over age 25.⁶³ OCs reduce menstrual flow and presumably decrease retrograde menses, which is generally believed to contribute to endometriosis. Women who have endometriosis can be treated with extended or continuous use of strong progestogenic OCs to induce pseudo-decidualization of the endometriotic implants and to reduce symptoms during use.⁶⁴ Such treatment is not curative, however; the implants undergo atrophy during treatment but remain ready for reactivation when OCs are stopped.⁶⁵
6. **Decrease risk of iron deficiency anemia.** By reducing menstrual blood loss, women increase their hemoglobin and ferritin

levels.⁶⁶ This benefit is especially important for women with sickle cell anemia or Von Willebrand's disease, women using anticoagulants or anticonvulsants, and women with fibroids or other causes of primary or secondary menorrhagia (see Chapter 6, Menstrual Problems and Common Gynecologic Concerns).

7. **Treatment of hot flashes and other hormonal fluctuation symptoms** in perimenopausal women.^{67,68} (See Chapter 5 on Menopause for more discussion.)

Other potential health benefits

1. **Reduced risk of developing rheumatoid arthritis (RA).** Although early studies suggested that OC use was associated with a reduced risk of RA, there is still controversy about this benefit. One meta-analysis suggested that instead of protecting against the condition, OC use slowed progression of RA,⁶⁹ and a later metaanalysis found no protective effect.⁷⁰
2. **Reduced risk of uterine fibroids.** OC users have fewer fibroids, especially with long-term use,⁷¹ but use early in life may increase risk.⁷² OCs may control menorrhagia due to uterine myoma. In fact, in many settings, women with moderate-sized fibroids must fail to respond to medical management for menorrhagia (usually with OCs) before they can be considered for surgery.
3. **Reduced risk of fractures.** The impact OC use has on the risk for fracture is still under question. Studies have shown a lower risk for postmenopausal hip fractures,⁷³ increased bone mineral density (BMD) especially in the lumbar spine,⁷⁴ and a slight reduction in osteoporosis.⁷⁵ However, one prospective study reported an increased risk of osteoporosis.⁷⁶ A comprehensive review of 13 studies of low-dose OCs use found 9 studies showed favorable impact on BMD, and 4 were neutral.⁷⁷ If there is a benefit, it may only be in at-risk women with low estrogen levels. OC use increases BMD in young women with hypothalamic amenorrhea.⁷⁸ OC use in women with osteopenia due to anorexia nervosa is not sufficient to protect bone, but when added to anabolic agents such as insulin growth factor (IGF), OC use significantly improves that agent's effectiveness.⁷⁹ OC use modulates the negative impact of smoking in young women and improves BMD in young women with irregular menses.⁸⁰
4. **Favorable impact on lipids.** EE increases HDL cholesterol and reduces LDL cholesterol. Progestins diminish the magnitude of this favorable impact; the more androgenic formulations have a more pronounced negative effect. Although triglyceride levels increase somewhat with estrogen-containing contraception, there is little concern because those remnants are not atherogenic. However, estrogen-containing contraceptives should be avoided

if their use will be anticipated to raise triglyceride levels to 500 mg/dl and place the woman at risk for pancreatitis.

5. **Improved lung mechanics.**⁸¹
6. **Possible reduced risk for colorectal cancer.**⁸²
7. **Influence on sexual enjoyment.** OC use may increase sexual pleasuring, either by increasing libido (less concern about pregnancy) or increasing lubrication. On the other hand, some OC users report decreased libido and more vaginal dryness.
8. **Fewer episodes of seizures, porphyria, and asthma.** These conditions may worsen during a woman's menses. Continuous use of OCs can prevent these problems for months at a time.
9. **Vitamin fortification.** Iron has been added to some placebo pills at the end of the cycle. Work is underway to add 400 mcg of folic acid to both active and placebo pills. Iron deficiency is associated with anemia, and maternal folic acid deficiency contributes to neural tube defects in offspring.

INDICATIONS

Considering the wide range of benefits OCs offer, their use can be particularly attractive for women who desire reversible contraception and have hormone-related problems. It should be noted that OCs might be beneficial in treatment of some of the following conditions (after underlying pathology has been ruled out), even if the woman is not at risk for pregnancy:

- Heavy, painful, irregular menstrual bleeding, or menorrhagia (dysmenorrhea, oligomenorrhea)
- Dysfunctional uterine bleeding
- Recurrent luteal phase ovarian cysts
- Family history of ovarian cancer
- Personal risk for endometrial cancer
- Acne or hirsutism
- Polycystic ovary syndrome (PCOS)

In addition, extended use OC may be particularly helpful for women with

- Premenstrual symptoms (PMS)
- Endometriosis
- Mentally challenged women whose monthly menstruations terrify them and provide a hygiene challenge to their caregivers.
- Anemia due to menorrhagia
- Dysmenorrhea

00803750

Finally, OCs with levonorgestrel or norgestrel may be used for emergency contraception. New studies suggest that OCs with norethindrone may be used for emergency contraception if the more effective formulations are not available (see Chapter 12 on Emergency Contraception).⁸³

DISADVANTAGES AND HEALTH COMPLICATIONS

Inform women that OC use may be associated with some disadvantages, many of which can be overcome or managed. Consult the section on Managing Side Effects. Some disadvantages are also discussed in the section on Special Issues.

General Disadvantages

1. **Daily administration.** Inconsistent or incorrect use of OCs reduces protection from the risk of pregnancy and increases the incidence of side effects, such as breakthrough bleeding.
2. **Expense and access.** In many states, insurance plans are not required to cover contraception, so women must pay for their OCs. Often, women are required to return to pharmacies each month to purchase another package. The mismatch between calendar months with 30 to 31 days and pill packs with only 28 pills can present challenges in use.
3. **Need for storage and ready access.** Adolescent women or women whose partners do not want them to use contraception may not have a place to hide their pills. Practitioners need to confirm that the patient's plans for storage are realistic (school lockers are not an answer) and guide them to more private contraceptive methods, if needed. Homeless women and women who travel extensively may have difficulty storing their pill packs.
4. **No protection against STIs.** Women at risk for STIs may use OCs, but they should be advised to reduce their risk for infection by confining their activity to mutually monogamous, uninfected partners, or by using condoms with every act of coitus.

Health Complications

1. **Myocardial infarction (MI).** A pivotal U.S. study showed that low-dose OCs (<50mcg EE) do not significantly increase the risk of MI or stroke in healthy, non-smoking women.⁸⁴ Compared to never-users, current users as a group had a relative risk of 1.3 for MI; most of the increased risk was seen in women with known risk factors. A second study supported those findings.⁸⁵ Recent metaanalysis of the literature demonstrated that overall current use of OCs increased the risk of MI by 2.48 times. Pills with 20 mcg EE did not increase the risk of MI.⁸⁶ Large increases, by

factors of 7 to more than 100, have been observed in the relative risk (RR) of MI and ischemic stroke among OC users who also smoke or have hypertension.⁸⁷ The attributable risk of death from cardiovascular disease from low-dose OC use is 0.06 per 100,000 nonsmokers age 15 to 34 and 3.0 per 100,000 nonsmokers aged 35 to 44. However, the risk of death attributable to OC use by low-risk women of any age is less than their risk of mortality from pregnancy.⁸⁸

In an interesting analysis of those data, it was observed that nearly 75% of cases of MI could be attributed to smoking.⁸⁹ The third-generation OCs showed no increase in the risk of MIs, but the second-generation formulations apparently doubled the risk.⁸⁶ The increase in heart attacks seen with use of combined hormonal contraceptives is due to arterial thrombosis caused by estrogen. This is why women with underlying atherosclerotic coronary vessel damage from smoking, hypertension, and hyperlipidemia are more vulnerable. The effect is reversible. After women stop taking the pill, their risks for MI return to baseline. Once women over age 40 have stopped smoking for 3 to 12 months, they may be candidates for OC use if they have no other contraindications. Women with risk factors for MI may still be candidates for progestin-only methods.

2. **Stroke in high-risk women.** In 2002, a World Health Organization (WHO) panel found no significant increased risk of ischemic or hemorrhagic stroke among nonsmoking women with no history of migraine headaches who use low-dose (<35 mcg EE) OCs,⁹⁰ as did a subsequent study.⁹¹ However, OC users who smoke or are hypertensive have a three-fold risk of hemorrhagic stroke compared to those who do not have those risk factors. WHO studies found a significant increase in the risk of ischemic stroke, but not hemorrhagic stroke, among OC users who experienced migraine with aura (odds ratio 3.0, CI 1.3–11.3) and a nonsignificant increase in OC users who reported migraine without aura (OR 3.0, CI 0.7–148) (see Headache section in Managing Side Effects, below).⁹² The WHO panel stated that migraineurs with aura have a higher risk of stroke than those without aura, but no study had sufficient proof to examine risk of stroke by type of migraine.⁹³ There is no difference between second- and third-generation formulations.⁹⁴ OC patient package inserts state that the relative risk of hemorrhagic stroke associated with OC use is reported to be 1.2 for non-smokers, 7.6 for smokers, and 25.7 for severe hypertensives. The risk is also greater in older women.⁹⁵
3. **Venous thromboembolism (VTE).** VTE can develop in different organ systems and present with different symptoms as listed on Table 19-2. The rate of thrombosis is 4 to 5 for every 100,000 reproductive-age women, 12 to 20 for low-dose OC users, and 48

Table 19-2 Circulatory diseases attributable to pills

Diagnosis	Location of Pathology	Symptoms
Thrombophlebitis	Lower leg	Calf pains, swelling, heat or tenderness
Thrombophlebitis	Thigh	Pain, heat, or redness
Pulmonary embolism	Lung	Cough, including coughing up blood, chest pain; shortness of breath
Myocardial infarction	Heart	Chest pain, left arm and shoulder pain, shortness of breath, weakness
Thrombotic stroke	Brain	Headache, weakness or numbness, visual problem, sudden intellectual impairment
Hemorrhagic stroke, including subarachnoid hemorrhage	Brain	Headache, weakness or numbness, visual problem, sudden intellectual impairment
Retinal vein thrombosis	Eye	Headache, complete or partial loss of vision
Mesenteric vein thrombosis	Intestines	Abdominal pain, vomiting, weakness
Pelvic vein thrombosis	Pelvis	Lower abdominal pain, cramps

Source: Stewart F, et al. (1987).

to 60 for pregnant women.^{96,97} Pills with 35 mcg EE are associated with a lower risk of VTE than are 50 mg formulations.⁹⁸⁻¹⁰⁰ The risk for VTE is highest in the first 1 to 2 years of OC use and then decreases over time. The effects are reversible. Past use of OCs is not associated with increased risk. Smoking does not add to the risk.

Estrogen increases liver production of a variety of clot promoting factors (such as factor VII, factor VIII, factor X and fibrinogen), decreases the production of clot lysing factors (such as antithrombin III and protein S), and increases platelet activity. Progestins alone have no impact on the clotting system, but when combined with estrogen they generally temper estrogen's actions or maintain neutrality. In the mid 1990s, international studies indicated that pills containing the progestins desogestrel and gestodene (not available in the United States) may be associated with higher rates of thrombosis than the formulations containing levonorgestrel and norgestrel.⁹⁸⁻¹⁰⁰ U.S. labeling reflects these findings. Since then, it has been shown that there were confounding factors such as duration of use, selection bias (healthy user effect), and detection biases that may have influenced those study outcomes. Norgestimate was not included in the early international studies but was implicated in a subsequent transnational study.¹⁰¹ Because the new compound, drospirenone,

has antiandrogenic effects, it may also allow fuller expression of estrogen's thrombotic impact.^{102,103}

In most healthy women, estrogen and progestin together have no clinically significant impact on the coagulation system. Risk factors that place a woman at increased risk for venous thrombosis include obesity, previous venous compromise, and immobilization. However, the increase in VTE risk seen with OC use is most frequently due to inherited disorders such as factor V Leiden mutation or Protein S and C synthesis disorders. The factor V Leiden mutation explains 30% of all deep venous thromboses. In the United States, it is estimated that 5.3% of Caucasians, 2.2% of Hispanics, 1.2% of Blacks and Native Americans, and 0.5% of Asians carry Leiden mutations. Caucasians have a common genetic mutation in prothrombin, which affects 0.7% to 4% of that population.¹⁰⁴ Heterozygous factor V Leiden mutation carriers have thrombotic risk 6 to 8 times higher (24 to 40/100,000), and homozygous carriers have risk about 10 times greater than in the general population. When a carrier uses OCs, her VTE risk rises to 120 to 150/100,000 a year.¹⁰⁵ (For further discussion, see section on Patient Selection.)

4. **Hypertension.** OCs increase circulating levels of angiotensin II. Some women are very sensitive to angiotensin II levels, which can increase both their diastolic and systolic blood pressure readings. Both estrogen and progestin enhance aldosterone activity, which results in fluid retention, which, in turn, also contributes to an increase in blood pressure. The vast majority of women who use OCs will have no significant increase in either diastolic or systolic blood pressure measurements, although a 3 to 5 mm rise is not uncommon. However, 1% to 3% of women who use modern, low-dose OCs will, over time, experience increases in their blood pressure readings, which, if attributable to OC use, will normalize within 3 months of stopping estrogen-containing contraceptives. The women whose readings do not return to normal should undergo a standard work-up, although most will be found to have essential hypertension. Some women may need to begin antihypertensive agents as well as discontinuing OCs.
5. **Glucose tolerance and diabetes.** OCs currently available in the United States do not adversely affect carbohydrate metabolism.¹⁰⁶ Older OC formulations with high doses of sex steroids had a more profound impact on glucose tolerance and in some instances resulted in hyperglycemia with hyperinsulinemia. In the CARDIA study, current use of OCs was associated with lower glucose levels and perhaps with a lower odds ratio of diabetes.¹⁰⁷ Concerns have been raised about OC use in women at risk for developing diabetes because progesterone is a competitive inhibitor of the insulin

00803752

receptor and estrogen influences the release of insulin from the pancreatic islet cells and decreases insulin sensitivity.¹⁰⁸ High-risk women, such as those with a history of gestational diabetes who used OCs with low progestin content (Ovcon-35), had no higher risk of developing glucose intolerance or overt diabetes than the controls who used non-hormonal methods when both groups were studied for up to 7 years.¹⁰⁹

6. **Gallbladder disease.** Recent studies of low-dose OCs do not show the increased risk of cholelithiasis and cholecystitis associated earlier with high-dose OCs. However, it may still be possible that low-dose OCs accelerate the development of symptomatic gallbladder disease in women with preexisting stones or sludge. OCs do not increase the risk of gallbladder cancer.¹¹⁰
7. **Cholestatic jaundice.** The active transport of bile can be impaired by high-dose combined hormonal contraceptives, resulting in cholestatic jaundice with pruritus. This condition reverses with discontinuation of hormones. The incidence in the general population using low-dose formulations is not known but is assumed to be very rare.
8. **Hepatic neoplasms.** Benign liver tumors have been associated with the use of high-dose OCs, especially long-term use. Focal nodular hyperplasia may be increased nearly 3-fold in OC users.¹¹¹ Adenomas are the most significant, since they can cause rupture of the liver capsule, extensive intraperitoneal hemorrhage, and even death. Women may or may not have abdominal pain with adenomas; their liver function tests are usually normal. Palpate the liver edge as part of the annual physical exam. If the liver is enlarged or tender, discontinue hormonal contraception and evaluate with MRI or CT tests; ultrasound is not reliable. Tumor regression is expected after stopping OCs.

Hepatocellular carcinoma risk is not increased with OC use.¹¹² Use of hormonal contraception by high-risk women (with chronic hepatitis B virus) did not appear to increase the risk of hepatitis cellular carcinoma beyond their baseline elevated risk.

9. **Chlamydia/HIV.** Women who use OCs are at increased risk for acquiring chlamydia cervicitis.^{113,114} In a study of Kenyan professional sex workers, users of OCs had an increased risk (hazard ratio 1.8, CI 1.1–2.9) of becoming infected with chlamydia when compared with women using no contraceptives.¹¹⁵

OCs influence transcription of natural antimicrobials in the human endometrium, which might increase a woman's vulnerability to upper-tract chlamydia or HIV infection.¹¹⁶ Although a recent study shows that OCs thicken the vaginal epithelium,¹¹⁷

hormonal contraception might increase a woman's vulnerability to HIV infection by reducing its barrier protection, by increasing the number or permissiveness of susceptible cells, or by directly affecting viral expression.¹¹⁸ Clearly, all women at risk for STIs should limit their sexual activity to one uninfected, monogamous partner or, at a minimum, use latex or polyurethane condoms with every sexual act.

10. **Melanoma.** A pooled analysis of 10 case-controlled studies involving nearly 2,400 cases of melanoma revealed no correlation between OC use and the development of melanoma. No effect of duration of use or current use was observed.¹¹⁹ However, it is recommended that women with a history of melanoma refrain from getting pregnant or using hormonal contraception for at least 3 years after their original therapy, since the risk of recurrence is highest at this time.
11. **Leiomyoma** (uterine fibroids) contain both estrogen and progesterone receptors. Since fibroids often shrink after menopause, when estrogen levels decrease, it has been suggested that estrogen-containing contraceptives might increase the growth of these benign uterine tumors. However, clinical studies with low-dose OCs have found no impact on the risk of developing new fibroids or increasing the size of pre-existing fibroids.^{120–122} In fact, OCs are often used to control excessive menstrual bleeding caused by fibroids.
12. **Cervical dysplasia and cervical carcinoma.** OC users have a statistically significant higher risk of developing cervical dysplasia compared to women who use no method of contraception or who rely on tubal ligation. Cervical dysplasia and cervical carcinoma are caused by the human papillomavirus (HPV), especially HPV 16 and 18. OC users may have more unprotected intercourse with multiple partners. However, combined hormonal methods cause eversion of the cervical os, which not only increases metaplasia in nulliparous women but exposes those vulnerable metaplastic cells to HPV. OC use may be associated with artifacts that mimic ASC-US (glycogen vacuoles create perinuclear halos in OC users) on liquid-based cytology tests. Reflex HPV testing will demonstrate that two-thirds of those women have no virus.¹²³

OC users do not need to have cervical cytology testing more frequently than required by their other risk factors. Similarly, they do not need to be tested with more sensitive cytologic modalities because they use OCs.

Women who use OCs for more than 5 years and who are infected with HPV have a 3- to 4-fold increased risk for in situ and invasive

00803753